RA Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

RA Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-90,000	Closed	-$2.93M	–	106
2021 Q4	$2.93M	Hold	90,000	–	–	0.05%	97
2021 Q3	$4.02M	Hold	90,000	–	–	0.06%	91
2021 Q2	$4.91M	Hold	90,000	–	–	0.08%	86
2021 Q1	$6.73M	Buy	+90,000	New	+$9.35M	0.1%	78

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RA Capital Management's SYRS Position: Q1 2022 in Review

RA Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2022, closing a stake of 90,000 shares — an estimated $2.93M sold.

RA Capital Management first reported a position in SYRS in Q1 2021 and held it in 4 quarters. The position peaked at $6.73M in Q1 2021. 94 funds tracked by Wall St. Rank hold SYRS as of Q1 2022.

RA Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
RA Capital Management sold 90,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $2.93M.
RA Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
RA Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $6.73M in Q1 2021.
94 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.